Circulating Tumor DNA and Tissue Testing for Pancreatobiliary Tumors

Does circulating tumor DNA (ctDNA) correlate with next-generation sequencing (NGS) of tissue samples in patients with pancreaticobiliary tumors, and can it help estimate treatment response?In this cohort study with 790 patients, ctDNA testing significantly correlated with tissue NGS in finding actionable alterations for patients with pancreatic ductal adenocarcinoma and cholangiocarcinoma. Additionally, serial ctDNA testing found markers associated with higher odds of progressive disease.The findings of this study suggest that ctDNA testing can be used when tissue specimens are insufficient for analysis and can be complementary to tissue-based testing; ctDNA could also act as a marker of response and identify resistance mechanisms.

Corresponding Author: Hani Babiker, MD, Division of Hematology-Oncology, Department of Medicine, Mayo Clinic Florida, 4500 San Pablo Rd S, Jacksonville, FL 32224 (Babiker.hani@mayo.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.